October 2025
1. ARGYRIOU A, Wadsworth MH 2nd, Fienman J, Gonzalez-Sanchez AC, et al
   Innate immune cell subsets are enriched in synovial fluid of ACPA-negative rheumatoid arthritis and characterized by distinct type I IFN gene signatures.
   Ann Rheum Dis. 2025 Oct 3:S0003-4967(25)04299-2. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
2. DE GIUSEPPE A, Deichsel A, Reese A, Kleimann S, et al
   Collagen-binding integrin alpha11beta1 contributes to joint destruction in arthritic hTNFtg mice.
   Ann Rheum Dis. 2025;84:1649-1659.
   

   >> Share

   
   September 2025
3. HERNANDEZ-CRUZ B
   Response to correspondence about our article Hernandez-Cruz B, Otero-Varela L, Freire-Gonzalez M, Busquets-Perez N, Garcia Gonzalez AJ, Moreno-Ramos M, et al. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profi
   Ann Rheum Dis. 2025 Sep 30:S0003-4967(25)04322-5. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
4. BLANK RB, Bu K, Zhang X, Chen W, et al
   Short-chain fatty acids and their gut microbial pathways distinguish rheumatoid arthritis in discordant monozygotic twins.
   Ann Rheum Dis. 2025 Sep 29:S0003-4967(25)04363-8. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
5. DAVID P, Macleod T, Altaie A, Shi Y, et al
   Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis.
   Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
6. GILES JT, Charles-Schoeman C, Buch MH, Dougados M, et al
   Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.
   Ann Rheum Dis. 2025 Sep 23:S0003-4967(25)04360-2. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
7. SANTIAGO-LAMELAS L, Castro-Santos P, deAndres-Galiana EJ, Fernandez-Martinez JL, et al
   Identification of a novel transcriptome signature for predicting the response to anti-TNF-alpha treatment in patients with rheumatoid arthritis.
   Ann Rheum Dis. 2025 Sep 3:S0003-4967(25)04302-X. doi: 10.1016/j.ard.2025.
   

   >> Share

   
   
8. WILEY MM, Radziszewski M, Khatri B, Joachims ML, et al
   Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
   Ann Rheum Dis. 2025;84:1512-1527.
   

   >> Share

   
   
9. BOUCLY A, Mitrovic S, Carmagnat M, Savale L, et al
   Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15.
   Ann Rheum Dis. 2025;84:1538-1548.
   

   >> Share

   
   August 2025
10. DE LIMA J, Boutet MA, Bortolotti O, Chepeaux LA, et al
    Spatial mapping of rheumatoid arthritis synovial niches reveals a LYVE1(+) macrophage network associated with response to therapy.
    Ann Rheum Dis. 2025 Aug 22:S0003-4967(25)04292-X. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
11. GIOLLO A, Salvato M, Frizzera F, Khalid K, et al
    Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis.
    Ann Rheum Dis. 2025 Aug 21:S0003-4967(25)04288-8. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
12. TSALIKI M, Cavett J, Kurien BT, Bruxvoort C, et al
    A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjogren's disease.
    Ann Rheum Dis. 2025;84:1354-1362.
    

    >> Share

    
    
13. KERSCHBAUMER A, Steiner M, Pruckner P, Wildner B, et al
    Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.
    Ann Rheum Dis. 2025 Aug 1:S0003-4967(25)04243-8. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    July 2025
14. TRIAILLE C, Durez P, Smolen JS, McInnes IB, et al
    Precision medicine and the chaos theory in rheumatoid arthritis.
    Ann Rheum Dis. 2025 Jul 31:S0003-4967(25)04239-6. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
15. WANG H, Nugteren S, Groenland RJ, van der Meulen S, et al
    Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens.
    Ann Rheum Dis. 2025 Jul 18:S0003-4967(25)04183.
    

    >> Share

    
    
16. BACKLUND R, Bergstrom U, Compagno M, Arvidsson L, et al
    Quantified intakes of key diet components and the risk of developing rheumatoid arthritis: Results from a nested case-control study.
    Ann Rheum Dis. 2025 Jul 10:S0003-4967(25)04175.
    

    >> Share

    
    
17. BOWMAN SJ, Seror R, Porcher R, Arends S, et al
    Primary Sjogren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjogren's Syndrome: an Interventional Trial based on stratifYing patients (NECESS
    Ann Rheum Dis. 2025;84:1068-1089.
    

    >> Share

    
    
18. MEUDEC L, Goudarzi N, Silva-Saffar SE, Pascaud J, et al
    Development of salivary gland organoids derived from patient biopsies: a functional model of Sjogren's disease.
    Ann Rheum Dis. 2025;84:1195-1206.
    

    >> Share

    
    
19. PARODIS I, Lagutkin D, Lindblom J, Idborg H, et al
    New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Ann Rheum Dis. 2025;84:1180-1194.
    

    >> Share

    
    June 2025
20. SCHAEFER M, Purschke A, Zietemann V, Rudi T, et al
    Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.
    Ann Rheum Dis. 2025 Jun 25:S0003-4967(25)01024-6. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
21. HECK C, Zimmermann-Geller B, Haun S, Lotfering F, et al
    Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritis.
    Ann Rheum Dis. 2025 Jun 20:S0003-4967(25)01026-X. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
22. BLOMBERG NJ, Kristyanto H, Verstappen M, Neppelenbroek S, et al
    Autoreactive B cells in extremes of rheumatoid arthritis disease phenotypes.
    Ann Rheum Dis. 2025 Jun 17:S0003-4967(25)00965-3. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
23. JIN W, Wang Q, Jin C, Xue M, et al
    Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies' benefits.
    Ann Rheum Dis. 2025 Jun 12:S0003-4967(25)00898-2. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
24. WINTHROP KL, Bathon J, Kerschbaumer A, Isaacs JD, et al
    Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.
    Ann Rheum Dis. 2025;84:927-936.
    

    >> Share

    
    May 2025
25. TAKANASHI S, Takeuchi T, Kaneko Y
    Prognosis of older patients with multimorbidity who do not meet the definition of difficult-to-treat rheumatoid arthritis but have uncontrolled disease activity.
    Ann Rheum Dis. 2025 May 29:S0003-4967(25)00963-X. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
26. MARZEDA AM, Schwenzer A, Didov BS, Woolcock K, et al
    Investigating endogenous immune-mediated monocyte memory in rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 10:S0003-4967(25)00883-0. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
27. STEINZ N, Maarseveen TD, van den Akker EB, Cope AP, et al
    Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 9:S0003-4967(25)00900-8. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
28. HE Y, Sareila O, Johansson L, Agelii ML, et al
    Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 9:S0003-4967(25)00902-1. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
29. SHARMA SD, Hum RM, Nair N, Marshall L, et al
    Systematic review and independent validation of genetic factors of radiographic outcome in rheumatoid arthritis identifies a genome-wide association with CARD9.
    Ann Rheum Dis. 2025 May 8:S0003-4967(25)00897-0. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
30. VAN STEENBERGEN HW, Doornkamp F, Alivernini S, Backlund J, et al
    EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.
    Ann Rheum Dis. 2025 May 8:S0003-4967(25)00076-7. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
31. WIENTJES MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, et al
    Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial.
    Ann Rheum Dis. 2025 May 2:S0003-4967(25)00885-4. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
32. JAJODIA A, Mishra A, Doni Jayavelu N, Lambert K, et al
    Functional dissection of noncoding variants associated with rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 2:S0003-4967(25)00890-8. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
33. NASH P, Kerschbaumer A, Konzett V, Aletaha D, et al
    Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
    Ann Rheum Dis. 2025;84:664-679.
    

    >> Share

    
    
34. KONZETT V, Smolen JS, Nash P, Aletaha D, et al
    Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement.
    Ann Rheum Dis. 2025;84:680-696.
    

    >> Share

    
    April 2025
35. PECHER AC, Hensen L, Schairer-Marquardt R, Kowarik M, et al
    Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation.
    Ann Rheum Dis. 2025 Apr 30:S0003-4967(25)00886-6. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
36. WEI X, Wei C, Lin H, Xie Y, et al
    Anticitrullinated caspase 14 peptide antibody is a novel biomarker for seronegative rheumatoid arthritis.
    Ann Rheum Dis. 2025 Apr 29:S0003-4967(25)00892-1. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
37. HETLAND ML, Heiberg MS, Sokka-Isler T, Rudin A, et al
    Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and
    Ann Rheum Dis. 2025 Apr 4:S0003-4967(25)00819-2. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
38. HAUSER B, Merriman A, Foley J, Golla J, et al
    Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures.
    Ann Rheum Dis. 2025;84:554-561.
    

    >> Share

    
    
39. TRYPOSKIADIS K, Nayar S, Pucino V, Smith CG, et al
    Increasing the number of minor salivary glands from patients with Sjogren's disease improves the diagnostic and measurement precision of the histological focus score.
    Ann Rheum Dis. 2025;84:601-608.
    

    >> Share

    
    
40. VAN DER HELM-VAN MIL AHM, Aletaha D
    How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence.
    Ann Rheum Dis. 2025;84:521-528.
    

    >> Share

    
    
41. SEBBAG E, Molina-Collada J, Ndoye R, Aletaha D, et al
    Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
    Ann Rheum Dis. 2025;84:643-652.
    

    >> Share

    
    March 2025
42. CHARLTON RA, Gates E, Coates LC, Galloway J, et al
    Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set.
    Ann Rheum Dis. 2025 Mar 29:S0003-4967(25)00816-7. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
43. COLETTO LA, van Steenbergen HW, Di Mario C, Gessi M, et al
    Minimally invasive retrieval and characterisation of tenosynovial tissue in rheumatoid arthritis: a novel approach to study at-risk, active, and remission stages.
    Ann Rheum Dis. 2025 Mar 26:S0003-4967(25)00242-0. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
44. SIMON N, Rudjito R, Moll L, Sandor K, et al
    Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model.
    Ann Rheum Dis. 2025;84:421-434.
    

    >> Share

    
    February 2025
45. RAYENS E, Sy LS, Qian L, Wu J, et al
    Effectiveness and safety of the recombinant zoster vaccine in individuals >/=50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.
    Ann Rheum Dis. 2025 Feb 19:S0003-4967(25)00199-2. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
46. UCHIYAMA S, Ishikawa Y, Ikari K, Honda S, et al
    Mosaic loss of chromosome Y characterises late-onset rheumatoid arthritis and contrasting associations of polygenic risk score based on age at onset.
    Ann Rheum Dis. 2025 Feb 19:S0003-4967(25)00184-0. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
47. MOLANDER V, Bower H, Frisell T, Askling J, et al
    Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis.
    Ann Rheum Dis. 2025 Feb 17:S0003-4967(25)00075-5. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
48. FRAZZEI G, Landewe RBM, Wagenaar C, van de Stadt LA, et al
    Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort.
    Ann Rheum Dis. 2025 Feb 15:S0003-4967(25)00195-5. doi: 10.1016/j.ard.2025.
    

    >> Share

    
    
49. LIDAR M, Rimar D, David P, Jacoby E, et al
    CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
    Ann Rheum Dis. 2025;84:370-372.
    

    >> Share

    
    
50. ZHENG L, Gu M, Li X, Hu X, et al
    ITGA5(+) synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
    Ann Rheum Dis. 2025;84:232-252.
    

    >> Share

    
    
51. KRONZER VL, Williamson KA, Hayashi K, Atkinson EJ, et al
    Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.
    Ann Rheum Dis. 2025;84:221-231.
    

    >> Share

    
    
52. KUBO S, Miyazaki Y, Nishino T, Fujita Y, et al
    Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
    Ann Rheum Dis. 2025;84:210-220.
    

    >> Share

    
    
53. FUKUI S, Winkelmayer WC, Tedeschi SK, Marrugo J, et al
    Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
    Ann Rheum Dis. 2025;84:201-209.
    

    >> Share

    
    
54. LIU J, Jiang Y, Zhang S, Liu S, et al
    Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
    Ann Rheum Dis. 2025;84:188-200.
    

    >> Share

    
    
55. BAKER KF, Spierings J, Brom M, Radstake T, et al
    Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
    Ann Rheum Dis. 2025;84:153-157.
    

    >> Share

    
    January 2025
56. SCHER JU, Nayak R, Clemente JC
    Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
    Ann Rheum Dis. 2025;84:9-13.
    

    >> Share

    
    
57. VAN MULLIGEN E, Bour SS, Goossens LMA, de Jong PHP, et al
    Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
    Ann Rheum Dis. 2025;84:68-76.
    

    >> Share

    
    
58. RUYSSEN-WITRAND A, Brusq C, Masson M, Bongard V, et al
    Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.
    Ann Rheum Dis. 2025;84:49-59.
    

    >> Share

    
    
59. TAMAI H, Ikeda K, Miyamoto T, Taguchi H, et al
    Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Ann Rheum Dis. 2025;84:41-48.
    

    >> Share

    
    
60. DEANE KD, Holers VM, Emery P, Mankia K, et al
    Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
    Ann Rheum Dis. 2025;84:14-28.
    

    >> Share

    
    November 2024
61. LIDAR M, Rimar D, David P, Jacoby E, et al
    CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
    Ann Rheum Dis. 2024 Nov 27:ard-2024-226437. doi: 10.1136/ard-2024-226437.
    

    >> Share

    
    
62. LIU J, Jiang Y, Zhang S, Liu S, et al
    Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
    Ann Rheum Dis. 2024 Nov 27:ard-2024-226385. doi: 10.1136/ard-2024-226385.
    

    >> Share

    
    
63. FAUTREL B, Mitrovic S, De Matteis A, Bindoli S, et al
    EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.
    Ann Rheum Dis. 2024;83:1614-1627.
    

    >> Share

    
    
64. BINDOLI S, De Matteis A, Mitrovic S, Fautrel B, et al
    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
    Ann Rheum Dis. 2024;83:1731-1747.
    

    >> Share

    
    
65. DE MATTEIS A, Bindoli S, De Benedetti F, Carmona L, et al
    Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease.
    Ann Rheum Dis. 2024;83:1748-1761.
    

    >> Share

    
    
66. KACHLER K, Andreev D, Thapa S, Royzman D, et al
    Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis.
    Ann Rheum Dis. 2024;83:1691-1706.
    

    >> Share

    
    
67. 
    Correction: AB0159 Health related quality of life among patients with rheumatoid arthritis at Tikur Anbessa specialized Hospital. A Hospital- based cross sectional study.
    Ann Rheum Dis. 2024;83:e28.
    

    >> Share

    
    
68. BAKER KF, Spierings J, Brom M, Radstake T, et al
    Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
    Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772.
    

    >> Share

    
    
69. VENKEN K, Jarlborg M, Stevenaert F, Malfait TLA, et al
    Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smoking.
    Ann Rheum Dis. 2024 Nov 8:ard-2024-226284. doi: 10.1136/ard-2024-226284.
    

    >> Share

    
    
70. ROONEY CM, Jeffery IB, Mankia K, Wilcox MH, et al
    Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study.
    Ann Rheum Dis. 2024 Nov 8:ard-2024-226362. doi: 10.1136/ard-2024-226362.
    

    >> Share

    
    
71. KRONZER VL, Williamson KA, Hayashi K, Atkinson EJ, et al
    Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-226391. doi: 10.1136/ard-2024-226391.
    

    >> Share

    
    
72. ZHENG L, Gu M, Li X, Hu X, et al
    ITGA5(+) synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-225778. doi: 10.1136/ard-2024-225778.
    

    >> Share

    
    October 2024
73. RUYSSEN-WITRAND A, Brusq C, Masson M, Bongard V, et al
    Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo-controlled, double-blind trial.
    Ann Rheum Dis. 2024 Oct 29:ard-2024-226620. doi: 10.1136/ard-2024-226620.
    

    >> Share

    
    
74. 
    Correction: Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2024;83:e27.
    

    >> Share

    
    
75. FEIST E, Fleischmann RM, Fatenejad S, Bukhanova D, et al
    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
    Ann Rheum Dis. 2024;83:1454-1464.
    

    >> Share

    
    
76. KUBO S, Miyazaki Y, Nishino T, Fujita Y, et al
    Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226228. doi: 10.1136/ard-2024-226228.
    

    >> Share

    
    
77. TAMAI H, Ikeda K, Miyamoto T, Taguchi H, et al
    Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226350. doi: 10.1136/ard-2024-226350.
    

    >> Share

    
    September 2024
78. MAURO D, Lin X, Pontarini E, Wehr P, et al
    CD8(+) tissue-resident memory T cells are expanded in primary Sjogren's disease and can be therapeutically targeted by CD103 blockade.
    Ann Rheum Dis. 2024;83:1345-1357.
    

    >> Share

    
    
79. HOFFMANN MH, Kirchner H, Kronke G, Riemekasten G, et al
    Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases.
    Ann Rheum Dis. 2024;83:1233-1253.
    

    >> Share

    
    
80. VAN MULLIGEN E, Bour SS, Goossens LMA, de Jong PHP, et al
    Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
    Ann Rheum Dis. 2024 Sep 18:ard-2024-226286. doi: 10.1136/ard-2024-226286.
    

    >> Share

    
    
81. DEANE KD, Holers VM, Emery P, Mankia K, et al
    Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
    Ann Rheum Dis. 2024 Sep 6:ard-2023-224211. doi: 10.1136/ard-2023-224211.
    

    >> Share

    
    
82. QIU F, Xie D, Chen H, Wang Z, et al
    Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis.
    Ann Rheum Dis. 2024 Sep 4:ard-2024-225565. doi: 10.1136/ard-2024-225565.
    

    >> Share

    
    August 2024
83. PARKER M, Zheng Z, Lasarev MR, Larsen MC, et al
    Novel autoantibodies help diagnose anti-SSA antibody negative Sjogren disease and predict abnormal labial salivary gland pathology.
    Ann Rheum Dis. 2024;83:1169-1180.
    

    >> Share

    
    
84. KHIDIR SJH, Toes REM, van Mulligen E, van der Helm-van Mil AHM, et al
    Is tooth extraction as proxy for periodontal disease related to the development of RA? Lessons from a longitudinal study in the at-risk stage of clinically suspect arthralgia.
    Ann Rheum Dis. 2024;83:1227-1229.
    

    >> Share

    
    
85. FUKUI S, Winkelmayer WC, Tedeschi SK, Marrugo J, et al
    Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
    Ann Rheum Dis. 2024 Aug 21:ard-2024-226156. doi: 10.1136/ard-2024-226156.
    

    >> Share

    
    
86. TU J, Chen W, Huang W, Wang X, et al
    Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.
    Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. doi: 10.1136/ard-2024-226067.
    

    >> Share

    
    
87. WU H, Yuan H, Zhang J, He T, et al
    Helicobacter pylori upregulates PAD4 expression via stabilising HIF-1alpha to exacerbate rheumatoid arthritis.
    Ann Rheum Dis. 2024 Aug 6:ard-2023-225306. doi: 10.1136/ard-2023-225306.
    

    >> Share

    
    July 2024
88. HU F, Li X, Liu K, Li Y, et al
    Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study.
    Ann Rheum Dis. 2024 Jul 31:ard-2024-225564. doi: 10.1136/ard-2024-225564.
    

    >> Share

    
    
89. LEND K, Lampa J, Padyukov L, Hetland ML, et al
    Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.
    Ann Rheum Dis. 2024 Jul 30:ard-2024-226024. doi: 10.1136/ard-2024-226024.
    

    >> Share

    
    
90. VAN MULLIGEN E, Rutten-van Molken M, van der Helm-van Mil A
    Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
    Ann Rheum Dis. 2024 Jul 17:ard-2024-225746. doi: 10.1136/ard-2024-225746.
    

    >> Share

    
    
91. GENTE K, Feisst M, Marx D, Klika KD, et al
    Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
    Ann Rheum Dis. 2024;83:974-983.
    

    >> Share

    
    
92. GUPTA S, Yamada E, Nakamura H, Perez P, et al
    Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren's disease.
    Ann Rheum Dis. 2024;83:1034-1047.
    

    >> Share

    
    
93. YOSHIMURA Y, Yamanouchi M, Mizuno H, Ikuma D, et al
    Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
    Ann Rheum Dis. 2024 Jul 4:ard-2024-225914. doi: 10.1136/ard-2024-225914.
    

    >> Share

    
    June 2024
94. HAGHIKIA A, Hegelmaier T, Wolleschak D, Bottcher M, et al
    Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis.
    Ann Rheum Dis. 2024 Jun 27:ard-2024-226017. doi: 10.1136/ard-2024-226017.
    

    >> Share

    
    May 2024
95. BAERWALD C, Stemmler E, Gnuchtel S, Jeromin K, et al
    Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.
    Ann Rheum Dis. 2024 May 30:ard-2023-225414. doi: 10.1136/ard-2023-225414.
    

    >> Share

    
    
96. PISANIELLO HL, Lester SE, Russell O, Black R, et al
    The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
    Ann Rheum Dis. 2024 May 29:ard-2024-225696. doi: 10.1136/ard-2024-225696.
    

    >> Share

    
    
97. BURMESTER GR, Gottenberg JE, Caporali R, Winthrop KL, et al
    Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
    Ann Rheum Dis. 2024 May 23:ard-2024-225759. doi: 10.1136/ard-2024-225759.
    

    >> Share

    
    
98. LAGE-HANSEN PR, Svendsen N, Kirkham J, Nielsen SM, et al
    Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set.
    Ann Rheum Dis. 2024 May 22:ard-2024-225523. doi: 10.1136/ard-2024-225523.
    

    >> Share

    
    
99. BECKMANN D, Krause A, Hansen U, Kiener HP, et al
    Focal adhesion protein Lasp1 links the Arp2/3 complex to adherens junctions and promotes motility of arthritic fibroblast-like synoviocytes.
    Ann Rheum Dis. 2024;83:816-819.
    

    >> Share

    
    
100. LIU D, Kuang Y, Chen S, Li R, et al
     NAT10 promotes synovial aggression by increasing the stability and translation of N4-acetylated PTX3 mRNA in rheumatoid arthritis.
     Ann Rheum Dis. 2024 May 8:ard-2023-225343. doi: 10.1136/ard-2023-225343.
     

     >> Share

     
     April 2024
101. IKDAHL E, Semb AG, Kerola AM
     No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register.
     Ann Rheum Dis. 2024 Apr 23:ard-2024-225758. doi: 10.1136/ard-2024-225758.
     

     >> Share

     
     
102. LUO X, Ren Y, Chen Y
     Gender imbalance in expert panels of recommendations in rheumatology.
     Ann Rheum Dis. 2024;83:682-684.
     

     >> Share

     
     
103. HERNANDEZ-CRUZ B, Otero-Varela L, Freire-Gonzalez M, Busquets-Perez N, et al
     Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
     Ann Rheum Dis. 2024 Apr 9:ard-2023-225271. doi: 10.1136/ard-2023-225271.
     

     >> Share

     
     March 2024
104. COHEN P, Ziff D, Lipsky PE
     Morris Ziff.
     Ann Rheum Dis. 2024;83:417-420.
     

     >> Share

     
     
105. WINTHROP KL, Mease P, Kerschbaumer A, Voll RE, et al
     Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
     Ann Rheum Dis. 2024;83:409-416.
     

     >> Share

     
     
106. MELOKHINA V, Paulshus Sundlisaeter N, Sexton J, Sundin U, et al
     Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
     Ann Rheum Dis. 2024;83:540-541.
     

     >> Share

     
     February 2024
107. HE Y, Aoun M, Xu Z, Holmdahl R, et al
     Shift in perspective: autoimmunity protecting against rheumatoid arthritis.
     Ann Rheum Dis. 2024 Feb 27:ard-2023-225237. doi: 10.1136/ard-2023-225237.
     

     >> Share

     
     
108. VAN DER WOUDE D, Toes REM
     Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
     Ann Rheum Dis. 2024 Feb 20:ard-2023-224103. doi: 10.1136/ard-2023-224103.
     

     >> Share

     
     
109. 
     Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study.
     Ann Rheum Dis. 2024;83:e8.
     

     >> Share

     
     
110. 
     Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis.
     Ann Rheum Dis. 2024;83:e9.
     

     >> Share

     
     
111. TANG Z, Shi H, Liu HL, Cheng X, et al
     Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
     Ann Rheum Dis. 2024;83:e4.
     

     >> Share

     
     
112. BARBHAIYA M, Zuily S, Hendry AM, Manneville F, et al
     Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.
     Ann Rheum Dis. 2024;83:e5.
     

     >> Share

     
     
113. DAMOISEAUX J, van Beers J
     Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".
     Ann Rheum Dis. 2024;83:e6.
     

     >> Share

     
     
114. ERKAN D, Barbhaiya M, Zuily S, Bertolaccini ML, et al
     Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.
     Ann Rheum Dis. 2024;83:e3.
     

     >> Share

     
     
115. BARBHAIYA M, Zuily S, Bertolaccini ML, Willis R, et al
     Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
     Ann Rheum Dis. 2024;83:e7.
     

     >> Share

     
     
116. MIRO-MUR FA, Alijotas-Reig J, Anunciacion-Llunell A, Marques-Soares J, et al
     Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
     Ann Rheum Dis. 2024;83:e2.
     

     >> Share

     
     
117. PEZOT M, Nocturne G, Belkhir R, Henry J, et al
     Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
     Ann Rheum Dis. 2024;83:407-408.
     

     >> Share

     
     
118. DORNER T, Kaul M, Szanto A, Tseng JC, et al
     Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
     Ann Rheum Dis. 2024;83:360-371.
     

     >> Share

     
     
119. CROWSON CS, Atkinson EJ, Kronzer VL, Kimbrough BA, et al
     Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis.
     Ann Rheum Dis. 2024 Feb 8:ard-2023-225093. doi: 10.1136/ard-2023-225093.
     

     >> Share

     
     
120. SCHENNING LCM, Ottevanger R, Quint KD, Tas SW, et al
     An ulcerating skin tumour in a patient with rheumatoid arthritis.
     Ann Rheum Dis. 2024 Feb 5:ard-2023-225436. doi: 10.1136/ard-2023-225436.
     

     >> Share

     
     
121. HU F, Shi L, Liu X, Chen Y, et al
     Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-alpha in rheumatoid arthritis.
     Ann Rheum Dis. 2024 Feb 1:ard-2023-224878. doi: 10.1136/ard-2023-224878.
     

     >> Share

     
     January 2024
122. WU G, Cao B, Zhai H, Liu B, et al
     EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.
     Ann Rheum Dis. 2024 Jan 25:ard-2023-224852. doi: 10.1136/ard-2023-224852.
     

     >> Share

     
     
123. HECKERT SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, et al
     Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
     Ann Rheum Dis. 2024;83:161-168.
     

     >> Share

     
     
124. BONELLI M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al
     Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
     Ann Rheum Dis. 2024;83:139-160.
     

     >> Share

     
     
125. TANAKA H, Okada Y, Nakayamada S, Miyazaki Y, et al
     Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
     Ann Rheum Dis. 2024;83:242-252.
     

     >> Share

     
     
126. DREHER M, Witte T, Hoeper K, Assmann G, et al
     Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.
     Ann Rheum Dis. 2024;83:184-193.
     

     >> Share

     
     
127. SCHIFF AE, Wang X, Patel NJ, Kawano Y, et al
     Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
     Ann Rheum Dis. 2024 Jan 10:ard-2023-225162. doi: 10.1136/ard-2023-225162.
     

     >> Share

     
     
128. AVOUAC J, Hecquet S, Thomas M, Combier A, et al
     Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts.
     Ann Rheum Dis. 2024 Jan 5:ard-2023-225272. doi: 10.1136/ard-2023-225272.
     

     >> Share

     
     
129. TEUWEN MMH, van Weely SFE, Vliet Vlieland TPM, van Wissen MAT, et al
     Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.
     Ann Rheum Dis. 2024 Jan 3:ard-2023-224912. doi: 10.1136/ard-2023-224912.
     

     >> Share

     
     
130. BAKER JF, ODell JR, England BR, Giles JT, et al
     Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
     Ann Rheum Dis. 2024 Jan 3:ard-2023-225014. doi: 10.1136/ard-2023-225014.
     

     >> Share

     
     
131. 
     Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
     Ann Rheum Dis. 2024;83:e1.
     

     >> Share

     
     
132. CAO S, Li Y, Song R, Meng X, et al
     L-arginine metabolism inhibits arthritis and inflammatory bone loss.
     Ann Rheum Dis. 2024;83:72-87.
     

     >> Share

     
     
133. BIJLSMA JWJ
     Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy.
     Ann Rheum Dis. 2024;83:4-8.
     

     >> Share

     
     
134. BERRY JS, Tarn J, Casement J, Duret PM, et al
     Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
     Ann Rheum Dis. 2024;83:88-95.
     

     >> Share

     
     December 2023
135. AYMON R, Mongin D, Bergstra SA, Choquette D, et al
     Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
     Ann Rheum Dis. 2023 Dec 8:ard-2023-224670. doi: 10.1136/ard-2023-224670.
     

     >> Share

     
     
136. TRIAILLE C, Tilman G, Sokolova T, Loriot A, et al
     Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
     Ann Rheum Dis. 2023;82:1538-1546.
     

     >> Share

     
     
137. YAMADA H, Haraguchi A, Tsuru T, Kondo M, et al
     Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies.
     Ann Rheum Dis. 2023;82:1637-1638.
     

     >> Share

     
     November 2023
138. LIEN HJT, Pedersen TT, Jakobsen B, Flatberg A, et al
     Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.
     Ann Rheum Dis. 2023 Nov 30:ard-2023-224644. doi: 10.1136/ard-2023-224644.
     

     >> Share

     
     
139. PERTSINIDOU E, Saevarsdottir S, Manivel VA, Klareskog L, et al
     In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
     Ann Rheum Dis. 2023 Nov 27:ard-2023-224728. doi: 10.1136/ard-2023-224728.
     

     >> Share

     
     
140. MOULIN D, Millard M, Taieb M, Michaudel C, et al
     Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
     Ann Rheum Dis. 2023 Nov 24:ard-2023-224014. doi: 10.1136/ard-2023-224014.
     

     >> Share

     
     
141. GOLDMANN K, Spiliopoulou A, Iakovliev A, Plant D, et al
     Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.
     Ann Rheum Dis. 2023 Nov 18:ard-2023-224540. doi: 10.1136/ard-2023-224540.
     

     >> Share

     
     
142. SIMON TA, Dong L, Suissa S, Michaud K, et al
     Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
     Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356.
     

     >> Share

     
     
143. 
     Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
     Ann Rheum Dis. 2023;82:e227.
     

     >> Share

     
     
144. 
     Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
     Ann Rheum Dis. 2023;82:e222.
     

     >> Share

     
     
145. WOLLHEIM FA
     Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
     Ann Rheum Dis. 2023;82:1382-1386.
     

     >> Share

     
     
146. SAVIANO A, Manosour AA, Raucci F, Merlino F, et al
     New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
     Ann Rheum Dis. 2023;82:1415-1428.
     

     >> Share

     
     
147. SCHERLINGER M, Schaeverbeke T
     Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'.
     Ann Rheum Dis. 2023;82:e221.
     

     >> Share

     
     
148. OZEN G, Pedro S, Michaud K
     Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2023;82:1487-1494.
     

     >> Share

     
     October 2023
149. WESTHOVENS R, Verschueren P
     Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023.
     Ann Rheum Dis. 2023 Oct 30:ard-2023-224904. doi: 10.1136/ard-2023-224904.
     

     >> Share

     
     
150. KONZETT V, Kerschbaumer A, Smolen JS, Kristianslund EK, et al
     Definition of rheumatoid arthritis flare based on SDAI and CDAI.
     Ann Rheum Dis. 2023 Oct 27:ard-2023-224742. doi: 10.1136/ard-2023-224742.
     

     >> Share

     
     
151. VAN WESEMAEL TJ, Reijm S, Kawakami A, Dorjee AL, et al
     IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
     Ann Rheum Dis. 2023 Oct 3:ard-2023-224553. doi: 10.1136/ard-2023-224553.
     

     >> Share

     
     
152. 
     Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial.
     Ann Rheum Dis. 2023;82:e219.
     

     >> Share

     
     
153. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
     Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
     Ann Rheum Dis. 2023;82:e217.
     

     >> Share

     
     
154. MA KS, Chiang CH, Chen YW, Wang LT, et al
     Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production'.
     Ann Rheum Dis. 2023;82:e216.
     

     >> Share

     
     September 2023
155. KONZETT V, Kerschbaumer A, Smolen JS, Aletaha D, et al
     Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
     Ann Rheum Dis. 2023 Sep 27:ard-2023-224477. doi: 10.1136/ard-2023-224477.
     

     >> Share

     
     
156. FLEISCHMANN RM, van der Heijde D, Strand V, Atsumi T, et al
     Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
     Ann Rheum Dis. 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
     

     >> Share

     
     
157. YAP CF, Nair N, de Vries A, Loeff FC, et al
     HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2023 Sep 12:ard-2023-223955. doi: 10.1136/ard-2023-223955.
     

     >> Share

     
     
158. TAYLOR PC, Weinblatt ME, McInnes IB, Atsumi T, et al
     Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
     Ann Rheum Dis. 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
     

     >> Share

     
     April 2023
159. MEYER A, Sienes RE, Nijim W, Zanotti B, et al
     Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
     Ann Rheum Dis. 2023;82:483-495.
     

     >> Share

     
     
160. REUTER K, Rocca E
     Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e91.
     

     >> Share

     
     
161. ZHENG BK
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2023;82:e93.
     

     >> Share

     
     
162. GEORGIADIS AN, Pelechas E, Voulgari PV, Drosos AA, et al
     Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e89.
     

     >> Share

     
     
163. PLEIN S, Buch MH
     Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis et al.
     Ann Rheum Dis. 2023;82:e90.
     

     >> Share

     
     
164. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
     Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
     Ann Rheum Dis. 2023;82:e94.
     

     >> Share

     
     
165. ZERVOU MI, Goulielmos GN
     Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
     Ann Rheum Dis. 2023;82:e87.
     

     >> Share

     
     
166. CONRAD N, McInnes IB, Mcmurray JJV, Sattar N, et al
     Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
     Ann Rheum Dis. 2023;82:457-459.
     

     >> Share

     
     
167. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
     Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al.
     Ann Rheum Dis. 2023;82:e92.
     

     >> Share

     
     
168. MOLANDER V, Askling J
     Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
     Ann Rheum Dis. 2023;82:e88.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share